Asymmetric dimethylarginine in young people with Type1 diabetes: A paradoxical association with HbA1c

Diabetic Medicine

Volumn 28, Issue 6, 2011, Pages 685-691

  Marcovecchio, M L ^a,b   Widmer, B ^a   Turner, C ^c   Dunger, D B ^a,d   Dalton, R N ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CHIETI   (Italy)

^c EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

ADMA; Children and adolescents; HbA1c; Microalbuminuria; Type1 diabetes

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; INSULIN; N(G),N(G) DIMETHYLARGININE;

ADOLESCENT; AMINO ACID BLOOD LEVEL; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CREATININE URINE LEVEL; DISEASE ASSOCIATION; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; JUVENILE DIABETES MELLITUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MICROALBUMINURIA; SCHOOL CHILD; URINALYSIS;

ADOLESCENT; ALBUMINURIA; ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LONGITUDINAL STUDIES; MALE; RISK FACTORS;

EID: 79955963339     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03252.x     Document Type: Article

References (36)

1. Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 2006; 26: 203-228.
2. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 493: e1-e8.
3. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002; 45: 1609-1616.
4. Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006; 38: 126-136.
5. Mookerjee RP, Dalton RN, Davies NA, Hodges SJ, Turner C, Williams R et al. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transpl 2007; 13: 400-405.
6. Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007; 45: 62-71.
7. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type1 diabetes and coronary artery disease. Diabetes Care 2006; 29: 2528-2538.
8. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type1 diabetes. Diabetes Care 2004; 27: 765-769.
9. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003; 166: 279-284.
10. Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N et al. Soluble RAGE in type2 diabetes: association with oxidative stress. Free Radic Biol Med 2007; 43: 511-518.
11. Malecki MT, Undas A, Cyganek K, Mirkiewicz-Sieradzka B, Wolkow P, Osmenda G et al. Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in type2 diabetes. Diabetes Care 2007; 30: 2899-2901.
12. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type1 diabetic patients with diabetic nephropathy. Diabetes Care 2008; 31: 747-752.
13. Altinova AE, Arslan M, Sepici-Dincel A, Akturk M, Altan N, Toruner FB. Uncomplicated type1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 2007; 92: 1881-1885.
14. Paiva H, Lehtimaki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O et al. Plasma concentrations of asymmetric-dimethyl-arginine in type2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003; 52: 303-307.
15. Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Martini F, Scaglione GL et al. Role of asymmetric-dimethyl-L-arginine (ADMA) and nitrite/nitrate (NOx) in the pathogenesis of oxidative stress in female subjects with uncomplicated type1 diabetes mellitus. Diabetes Res Clin Pract 2009; 86: 173-176.
16. Sibal L, Agarwal SC, Schwedhelm E, Luneburg N, Boger RH, Home PD. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc Diabetol 2009; 8: 27.
17. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997; 15: 901-909.
18. Lucke T, Kanzelmeyer N, Kemper MJ, Tsikas D, Das AM. Developmental changes in the L-arginine/nitric oxide pathway from infancy to adulthood: plasma asymmetric dimethylarginine levels decrease with age. Clin Chem Lab Med 2007; 45: 1525-1530.
19. Brooks ER, Langman CB, Wang S, Price HE, Hodges AL, Darling L et al. Methylated arginine derivatives in children and adolescents with chronic kidney disease. Pediatr Nephrol 2009; 24: 129-134.
20. Jehlicka P, Stozicky F, Mayer O Jr, Varvarovska J, Racek J, Trefil L et al. Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type1. Physiol Res 2009; 58: 179-184.
21. Heilman K, Zilmer M, Zilmer K, Kool P, Tillmann V. Elevated plasma adiponectin and decreased plasma homocysteine and asymmetric dimethylarginine in children with type1 diabetes. Scand J Clin Lab Invest 2009; 69: 85-91.
22. Marcovecchio ML, Widmer B, Dunger DB, Dalton RN. Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with Type1 diabetes. Clin Sci (Lond) 2008; 115: 361-369.
23. Schultz CJ, Konopelska-Bahu T, Dalton RN, Carroll TA, Stratton I, Gale EA et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care 1999; 22: 495-502.
24. Cole TJ. The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990; 44: 45-60.
25. Twisk JWR. Applied Multilevel Analysis: A Practical Guide. Cambridge: Cambridge University Press, 2006.
26. Arslanian SA, Kalhan SC. Protein turnover during puberty in normal children. Am J Physiol 1996; 270: E79-E84.
27. Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OA et al. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia 2006; 49: 351-359.
28. Krzyzanowska K, Mittermayer F, Krugluger W, Schnack C, Hofer M, Wolzt M et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type2 diabetes. Atherosclerosis 2006; 189: 236-240.
29. Ahmed ML, Ong KK, Watts AP, Morrell DJ, Preece MA, Dunger DB. Elevated leptin levels are associated with excess gains in fat mass in girls, but not boys, with type1 diabetes: longitudinal study during adolescence. J Clin Endocrinol Metab 2001; 86: 1188-1193.
30. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type1 diabetes: prospective cohort study. Br Med J 2008; 337: a918.
31. Amin R, Schultz C, Ong K, Frystyk J, Dalton RN, Perry L et al. Low IGF-I and elevated testosterone during puberty in subjects with type1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects: the Oxford Regional Prospective Study. Diabetes Care 2003; 26: 1456-1461.
32. Amin R, Turner C, van Aken S, Bahu TK, Watts A, Lindsell DR et al. The relationship between microalbuminuria and glomerular filtration rate in young type1 diabetic subjects: The Oxford Regional Prospective Study. Kidney Int 2005; 68: 1740-1749.
33. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003; 4: 33-40.
34. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455.
35. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62: 339-345.
36. Valtonen P, Karppi J, Nyyssonen K, Valkonen VP, Halonen T, Punnonen K. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 828: 97-102.